共 50 条
[42]
Comparative Effectiveness, Time to Discontinuation, and Patient-Reported Outcomes with Baricitinib in Rheumatoid Arthritis: 2-Year Data from the Multinational, Prospective Observational RA-BE-REAL Study in European Patients
[J].
Rheumatology and Therapy,
2023, 10
:1575-1595
[46]
Factors Influencing Choice of Rituximab Versus an Alternative Tumor Necrosis Factor Inhibitor Following Tumor Necrosis Factor Inhibitor Failure in Patients with Rheumatoid Arthritis: Sub-Analysis of a Global, Observational Comparative Effectiveness Study.
[J].
ARTHRITIS AND RHEUMATISM,
2012, 64 (10)
:S198-S198
[47]
RANDOMIZATION TO PATIENT-REPORTED RAPID3 VERSUS PHYSICIAN-BASED CDAI TOOLS FOR PREDICTION OF TREATMENT RESPONSE AND ASSESSMENT OF PATIENT-REPORTED OUTCOMES IN RHEUMATOID ARTHRITIS PATIENTS RECEIVING CERTOLIZUMAB PEGOL: RESULTS FROM THE PREDICT STUDY
[J].
ANNALS OF THE RHEUMATIC DISEASES,
2014, 73
:382-382